Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod and Propranolol Interaction Study
NCT03882255Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ponesimod in multiple sclerosis (MS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Decrease from Baseline in Mean Hourly Heart Rate (Emax HR) on Day 5, Maximum Decrease from Baseline in Mean Hourly Heart Rate (Emax HR) on Day 19 and 2 more. Started Mar 2019; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03882255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882255.